Mirum was founded upon a drug treatment that RiverVest helped develop through Lumena – a Fund II company acquired by Shire in 2014.
After Shire deprioritized maralixibat trials in 2018, RiverVest helped reclaim the asset, provided scientific guidance to get the approval process back on track, and assembled a world-class leadership team to bring the drug to market.
LIVMARLI, a minimally absorbed ileal bile acid transporter inhibitor, is the first and only FDA- approved medication for treating a rare liver disease that affects 2,000 to 2,500 children in the United States. Mirum is advancing LIVMARLI and volixibat, also acquired from Shire, across five additional late-stage trials for high-need rare cholestatic liver diseases.
Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) are severe genetic diseases affecting 4,500 children in the U.S. and U.K. Most children with these diseases suffer from debilitating itching that disrupts sleep, stunts growth, and compels them to scratch themselves sometimes to the bone. The toll this takes on the psychological and social well-being of these children and their families is devastating. Many will require biliary diversion surgery or liver transplantation. Others will die from liver failure.
CEO Chris Peetz discusses Mirum’s robust pipeline
A Game-Changing Study
The Lumena team had the foresight to initiate a global database described by principal investigator Dr. Binita Kamath as a model for Academia and Industry collaboration. More than 100 physicians, scientists, and research coordinators from 35 countries share clinical, genetic, and laboratory data from ALGS patients in what has become The Global ALagille Alliance (GALA) Study.
Dr. Binita Kamath discusses the impact of GALA
- $120 million Series A in 2018
- IPO: July 2019 (NASDAQ: MIRM)
- Founded on a treatment co-developed by RiverVest
RiverVest helped build the company (Lumena) that initiated these studies and was instrumental in pulling together Mirum’s Series A financing, advising us through an IPO, and supporting our success as a public company.
Six years of data emerging from the GALA Study demonstrate significant, sustained event-free survival outcomes with maralixibat treatment vs. natural history in patients with ALGS.
This type of research doesn’t get funded from the standard federal agencies. It just doesn’t. And it’s been game changing!